China approves sugemalimab to treat unresectable NSCLC

Time : 16th of August 2022 02:33:26 PM

CStone Pharmaceuticals said that the NMPA of China approved the first anti-PD-1/PD-L1 monoclonal antibody, sugemalimab, for treating patients with unresectable non-small cell lung cancer (NSCLC) stage III whose disease did not progress after platinum-based chemoradiotherapy. Sugemalimab increased the overall survival rate in patients with NSCLC.

  PR Newswire